TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease | SGHT Stock NewsStockTitan·Aug 19 at 03:05 AMSGHT-3.65%
Sight Sciences names Rashid Kashif as chief legal officer in initial beneficial ownership filingPUBT·Aug 18 at 10:08 PMSGHT-3.65%
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy HaydenPUBT·Aug 10 at 12:22 PMSGHT-3.65%
Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%rttnews·Aug 7 at 02:35 AMENSC-1.17%MYO-4.03%
Sight Sciences GAAP EPS of -$0.08 beats by $0.06, revenue of $23.4M beats by $1.71Mbusinessinsider·Aug 6 at 04:01 AMSGHT-3.65%
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPSMarket Beat·Aug 6 at 01:26 AMSGHT-3.65%ALC-0.43%
Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platformsPUBT·Aug 5 at 10:34 PMSGHT-3.65%
SGHT: Q2 revenue up 20% YoY, guidance raised, and strong growth in both glaucoma and dry eye segmentsQuartr·Aug 5 at 10:05 PMSGHT-3.65%
